Your browser is no longer supported. Please, upgrade your browser.
ADYX Adynxx, Inc. daily Stock Chart
Adynxx, Inc.
Index- P/E- EPS (ttm)-8.10 Insider Own8.70% Shs Outstand0.82M Perf Week-43.04%
Market Cap1.85M Forward P/E- EPS next Y- Insider Trans- Shs Float0.58M Perf Month-64.34%
Income-6.30M PEG- EPS next Q- Inst Own10.80% Short Float3.83% Perf Quarter-76.77%
Sales1.80M P/S1.03 EPS this Y-43.90% Inst Trans-22.01% Short Ratio1.00 Perf Half Y-69.37%
Book/sh8.89 P/B0.25 EPS next Y- ROA-36.20% Target Price2.80 Perf Year-69.97%
Cash/sh9.39 P/C0.24 EPS next 5Y15.00% ROE-47.10% 52W Range1.92 - 19.15 Perf YTD-67.08%
Dividend- P/FCF- EPS past 5Y46.20% ROI-84.40% 52W High-88.25% Beta1.98
Dividend %- Quick Ratio8.20 Sales past 5Y4.30% Gross Margin14.50% 52W Low17.19% ATR0.69
Employees6 Current Ratio8.30 Sales Q/Q-80.00% Oper. Margin- RSI (14)27.06 Volatility30.14% 19.20%
OptionableNo Debt/Eq0.00 EPS Q/Q44.90% Profit Margin- Rel Volume0.24 Prev Close2.02
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume22.14K Price2.25
Recom- SMA20-51.26% SMA50-67.67% SMA200-71.96% Volume5,333 Change11.39%
Jun-12-19 12:32PM  Adynxx Stock to Move to OTC Market Following Receipt of Nasdaq Delisting Notice GlobeNewswire -39.23%
May-09-19 05:30PM  Adynxx, Inc. Receives Nasdaq Notice of Delisting or Failure to Satisfy an Initial Listing Rule or Standard GlobeNewswire -7.40%
Adynxx, Inc., a clinical-stage biopharmaceutical company, focuses to market various therapeutics for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including the initiation of two Phase II studies of brivoligide, its lead product candidate for postoperative pain. The company was founded in 2007 and is headquartered in San Francisco, California.